N = 2,300 名患者17 个中心 （100% monitored）西欧.pptVIP

N = 2,300 名患者 17 个中心 (100% monitored) 西欧 主要终点: TLF (复合终点包括：Cardiac Death, Target Vessel MI, Clinically driven TLR @ 12mo) 次要终点: Composite @ 30d, 6mo, 2 – 5 yr; angiographic optical coherence tomography(OCT) parameters @ 13 mo. 双重抗血小板治疗: ASA and clopidogrel/ticlid 6 months (per guidelines) 30d 6mo 4yr 3yr 2yr 12mo 13mo 5yr 临床/TLF 造影/OCT Resolute Stent n ? 1,150 Control Xience V Stent n ? 1,150 所有患者Co-PIs: Profs. Serruys, Silber, Windecker Clinical Endpoints 460 (20%) QCA subset 50 (2%) OCT Subset PCR 2010 1年结果 = 主要终点观测点 = 次要终点观测点 首次二代DES头对头真实世界对照试验 For distribution only in markets where Resolute DES has been approved. Not for distribution in the USA or Japan. ? 2010 Medtronic, Inc. All rights reserved. UC201006397EE 5/10 试验入组充分反映临床实际 For distribution only in markets where Resolute DES has been approved. Not for distribution in the USA or Japan. ? 2010 Medtronic, Inc. All rights reserved. UC201006397EE 5/10 Resolute达到主要终点12个月TLF For distribution only in markets where Resolute DES has been approved. Not for distribution in the USA or Japan. ? 2010 Medtronic, Inc. All rights reserved. UC201006397EE 5/10 Resolute：MACE和TVF发生率 For distribution only in markets where Resolute DES has been approved. Not for distribution in the USA or Japan. ? 2010 Medtronic, Inc. All rights reserved. UC201006397EE 5/10 Resolute：各个临床终点的出色表现 靶血管心梗 Resolute和Xience V：血栓无统计学差异 Resolute：56%血栓发生在术后5天内 早期的血栓对12个月的CD/TVMI无影响 p-values are based on Fishers Exact Test. p-values for outcome differences are unadjusted for multiple comparisons. Per protocol, a statistical difference was declared if the two-sided p-value was less than 0.05 RESOLUTE All Comers was not specifically designed or powered to individually compare endpoints shown above. Error bars indicate a point-wise two-sided 95% confidence interval (±1.96*SE). Standard Error based on the Greenwood Formula p-values for outcome differences are unadjusted for multiple comparisons. RESOLUTE All Comers was not specifically designed or powere